Press Releases

Back to previous page

ReGen Biologics to Present at First Albany’s Second Annual Orthopedics Conference on February 13, 2007

FRANKLIN LAKES, NJ -- Feb. 6, 2007 -- ReGen Biologics, Inc. (OTC:RGBI), an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets, has been invited to present to investors at First Albany’s Second Annual Orthopedics Conference.

The meeting will be held at Marina Village in San Diego, CA on February 13, 2007, with the ReGen presentation scheduled for 10:10 am PST.

About ReGen Biologics, Inc.
ReGen Biologics is a global orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, a meniscus application cleared for sale in Europe and marketed through the Company’s European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.  ReGen Biologics is headquartered in Franklin Lakes, NJ and operates a manufacturing plant in Redwood City, CA. For more information on ReGen, visit www.regenbio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2005 annual report on Form 10-K/A and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the Web site maintained by the SEC at http://www.sec.gov.

Contacts:
ReGen Biologics, Inc.
Brion Umidi
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Cameron Associates
Al Palombo
Investor Relations
(212) 554-5488
al@cameronassoc.com